Liraglutide vs Semaglutide
How Liraglutide and Semaglutide differ on mechanism, dosing, and the strength of the evidence behind each.
How this is graded
Every compound below carries a REGEN research grade, from S (regulatory approval behind the use it is bought for) down to F (no clinical evidence). Ordering follows that grade rather than search volume, so the compound at the top is the one with the most evidence, not the one most often sold. Doses are those reported in published protocols and are not recommendations.
Liraglutide
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to human GLP-1, modified with a fatty-acid side chain for albumin binding and extended action. Unlike the once-weekly semaglutide and tirzepatide, liraglutide requires once-daily subcutaneous dosing, titrated slowly upward to limit gastrointestinal side effects. It's FDA-approved under two brand names: Victoza for type 2 diabetes and Saxenda for chronic weight management, each with its own titration schedule and maximum dose. As an older, well-characterized GLP-1, it has the longest real-world safety record of any compound in this class.
Semaglutide
Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist that slows gastric emptying, increases satiety, and improves insulin sensitivity and glucose control. Originally developed for type 2 diabetes, it has become a leading weight-loss therapy. Dosing is titrated up slowly over weeks to minimize gastrointestinal side effects like nausea. It directly affects metabolic markers — expect improvements in HbA1c, fasting glucose, and body composition. Not typically stacked with growth or healing peptides; used as a standalone metabolic tool.
Evidence compared
| Liraglutide | Semaglutide | |
|---|---|---|
| Research grade | Sgrade | Sgrade |
| Reported dose | 0.6–3.0 mg | 0.25–2.4 mg |
| Frequency | 1x daily (titrated) | 1x weekly (titrated) |
| Half-life | ~13 hours | ~7 days |
| Routes | subcutaneous | subcutaneous, oral |
| Tracked outcomes | — | Weight Loss, Immune Function, Body Composition, Muscle Growth, Cognitive Function |
| Contraindications | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy | personal/family history of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy |
Which has more behind it
Liraglutide and Semaglutide sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight. Both entries link through to the full reference, where the trial list and citations for each claim are set out in full.
Full Liraglutide reference · Full Semaglutide reference
At a glance
| Compound | Grade | Reported dose | Half-life |
|---|---|---|---|
| Liraglutide | Sgrade | 0.6–3.0 mg · 1x daily (titrated) | ~13 hours |
| Semaglutide | Sgrade | 0.25–2.4 mg · 1x weekly (titrated) | ~7 days |
Frequently asked questions
Liraglutide or Semaglutide, which has better evidence?
Liraglutide and Semaglutide sit at the same research grade (S), so the choice between them turns on mechanism and tolerability rather than evidence weight.
Can Liraglutide and Semaglutide be used together?
The catalog does not list Liraglutide and Semaglutide as a common pairing. Combining compounds does not combine their evidence.
What doses are reported for Liraglutide?
Published protocols report 0.6–3.0 mg, 1x daily (titrated). This is what the literature describes, not a recommendation.
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity · Wilding JPH, et al. · 2021
- FDA Approval Announcement for Wegovy (2021). · 2021
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. · Lincoff AM, Brown-Frandsen K, Colhoun HM et al. · 2023
- Semaglutide, a glucagon like peptide-1 receptor agonist with ... - NIH · Mahapatra MK, Karuppasamy M, Sahoo BM · 2022
- Semaglutide Mechanism of Action Review. PMC. · Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A · 2022
- Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. · McGuire DK, Marx N, Mulvagh SL et al. · 2025
- Semaglutide | C187H291N45O59 | CID 56843331 - PubChem - NIH
- Central Nervous System Effects of GLP-1 Agonists. Nature Medicine.
- Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized trial. · McGuire DK, Busui RP, Deanfield J et al. · 2023
- Semaglutide - StatPearls - NCBI Bookshelf
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021. · Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MT, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF · 2021
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. · Perkovic V, Tuttle KR, Rossing P et al. · 2024
- Molecular mechanisms of semaglutide and liraglutide as a ... · Tamayo-Trujillo R, Ruiz-Pozo VA, Cadena-Ullauri S, Guevara-Ramírez P, Paz-Cruz E, Zambrano-Villacres R, Simancas-Racines D, Zambrano AK · 2024